A major concern for medicinal products of biological origin is the potential risk of contamination with known or unknown viruses. Manufacturers of biopharmaceutical products (such as recombinant proteins and monoclonal antibodies, or products derived from blood, tissue, or urine) are required to assess the ability of their manufacturing process to produce a product that is safe for use in humans…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.